Stay updated on Iberdomide Combo with Elotuzumab in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Iberdomide Combo with Elotuzumab in Myeloma Clinical Trial page.

Latest updates to the Iberdomide Combo with Elotuzumab in Myeloma Clinical Trial page
- Check5 days agoChange DetectedThe page history shows a new revision tag (v3.4.2) and the removal of a prior government funding status notice, which do not affect study data or user-facing functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check12 days agoChange DetectedA new version entry (Revision: v3.4.1) was added to the record history, along with a site-wide notice about government funding and operating status; the previous version (v3.4.0) was removed from this history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check19 days agoChange DetectedUI changes include a glossary toggle and color-coding explanations for added (green) and deleted (red) items on the history page. The revision tag was updated to v3.4.0 and the No FEAR Act Data label was removed from the display.SummaryDifference1%

- Check33 days agoChange DetectedA new revision entry, Revision: v3.3.4, was added to the Study Record Versions list, and the previous Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check40 days agoChange DetectedA new Study Status entry on 2026-01-02 was added to the record history, and the 2024-12-02 entry was removed.SummaryDifference0.4%

- Check55 days agoChange DetectedRevision: v3.3.3 was added to the Study Record Versions list, indicating a new update to the record. The footer now omits the HHS Vulnerability Disclosure link and Revision: v3.3.2.SummaryDifference0.2%

Stay in the know with updates to Iberdomide Combo with Elotuzumab in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Iberdomide Combo with Elotuzumab in Myeloma Clinical Trial page.